跳至主要内容
临床试验/NCT00423982
NCT00423982Unknown4 期

Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty

Oslo University Hospital8 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2006年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
100
试验地点
8
主要终点
Cure defined as lack of clinical, biochemistry or radiological signs of infection at two years follow-up.

研究概览

简要总结

The number of patients requiring joint replacement is increasing due to its success in restoring function and pain relief, and the growing population of the elderly. One of the most serious complications of arthroplasty is joint prosthesis infection. Due to the absence of prospective, randomized, controlled studies, there is no consensus concerning diagnosis and treatment of prosthetic joint infections. The main objective of this trial is to evaluate the clinical efficacy of rifampin combination therapy versus monotherapy using cloxacillin or vancomycin in early staphylococcal infections after total hip and knee arthroplasty.

详细描述

The study is a controlled randomized multicentre trial with 8 participating centres in Norway. We will include patients with the diagnosis of early infections (within 4 weeks post operatively)after hip or knee replacement. Patients with clinical signs of infection are scheduled for a standardized soft tissue revision. Diagnosis of staphylococci must be established by arthrocentesis or at surgical revision, and must grow in at least 2/8 cultures.The patients will randomly be assigned to antimicrobial therapy with or without rifampin by a randomization programme. Antibiotics will be given for 6 weeks. Two years follow-up. The study end points are final follow-up visit after two years or relapse of infection.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Prosthetic joint infections category 2 or 3 (early post.op infections within 4 weeks).
  • Diagnosis of staphylococci.
  • Clinically and radiographically stable implants kept in place after revision.

排除标准

  • Infection with other microorganisms than staphylococci.
  • Less than 2 years of expected survival.
  • Predictable inability to comply with the treatment and/or follow-up visits.
  • Contraindication to the use of study medication including acute or chronic liver disease.
  • Lack of written consent.
  • Fertile women.
  • Patients taking less than 80% of the study medication.

研究组 & 干预措施

Rifampicin-combination therapy

Active Comparator

Cloxacillin or vancomycin in combination with Rifampicin. Treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.

干预措施: Rifampin-combination therapy (Drug)

Monotherapy

Active Comparator

Cloxacillin or vancomycin in the treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.

干预措施: Monotherapy (Drug)

结局指标

主要结局

Cure defined as lack of clinical, biochemistry or radiological signs of infection at two years follow-up.

时间窗: 2 years

次要结局

未报告次要终点

研究者

发起方
Oslo University Hospital
申办方类型
Other
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验

Rifampin Combination Therapy Versus Monotherapy in... | 临床试验